Clinical Scorecard: Dual Therapy for Myopia Control
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Combination of low-dose atropine and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. |
| Target Population | |
| Care Setting |
Key Highlights
- Combination therapy showed a statistically significant reduction in axial elongation compared to atropine alone.
- 40% of children receiving combination therapy exhibited no axial elongation over 12 months.
- Both atropine and DIMS lenses are established monotherapies, each reducing myopia progression by approximately 50–60%.
Guideline-Based Recommendations
Diagnosis
Management
- Consider combination therapy of low-dose atropine and DIMS lenses for myopia control, as supported by the ASPECT trial.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Combination therapy may enhance control of axial elongation.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
